© 2002 European Society of Cardiology
Effect of thalidomide on the skeletal muscle in experimental heart failure
a Internal Medicine Adria Hospital, 45011 Adria, (RO), Italy
b CNR Unit for Muscle Biology and Physiopathology, Department of Biomedical Sciences University of Padova, Padova, Italy
c Cardiovascular Pathology University of Padova, Padova, Italy
d Cardiac Physiology Gussago (BS), Italy
ldl{at}civ.bio.unipd.it
* Corresponding author. Tel.: +39-0426-940-451; fax: +39-049-827-6040
 |
Abstract |
|---|
Background: Tumour Necrosis Factor 
(TNF) has been shown to contribute to heart failure (CHF) progression.
Aims: We have tried to antagonise the detrimental effects of TNF on skeletal muscle apoptosis, by using thalidomide, a drug that inhibits its biosynthesis.
Methods: CHF was induced in 20 rats by injecting monocrotaline, which determines right ventricle (RV) failure. After 2 weeks, when CHF developed, 12 rats were treated with thalidomide 3.5.mg/kg per day for 2 weeks. Eight had saline and served as CHF controls.
Results: Thalidomide failed to decrease TNF and its second messenger sphingosine (SPH), but was able to prevent the shift toward the fast myosin heavy chains. In the Tibialis Anterior muscle of the thalidomide group, the degree of atrophy, the number of apoptotic nuclei and the levels of caspases, were similar to those of the CHF controls.
Conclusions: Thalidomide, at the doses used in this study, which are the same employed for the treatment of tubercolosis, leprosy, AIDS and cancer in humans, did not lower either TNF or SPH and only marginally influenced the apoptosis-induced muscle atrophy. Since other TNF blockers are under investigation for improving the clinical status of patients with CHF, the present data could be relevant in the design of randomised clinical trials in humans.
Key Words: Apoptosis • Cytokines • Heart failure • Skeletal muscle, TNF • Sphingosine
Received August 30, 2001; Revised October 31, 2001; Accepted January 17, 2002
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. A. Ghofrani, R. J. Barst, R. L. Benza, H. C. Champion, K. A. Fagan, F. Grimminger, M. Humbert, G. Simonneau, D. J. Stewart, C. Ventura, et al. Future perspectives for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S108 - S117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. Steffen, S. J. Lees, and F. W. Booth Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia J Appl Physiol, December 1, 2008; 105(6): 1950 - 1958. [Abstract] [Full Text] [PDF]
|
|